Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

阿帕蒂尼 医学 内科学 临床终点 不利影响 临床研究阶段 索拉非尼 肿瘤科 实体瘤疗效评价标准 化疗 外科 临床试验 胃肠病学 肝细胞癌
作者
Xiangrui Meng,Tao Wu,Yonggui Hong,Qingxia Fan,Zhonghai Ren,Yanzhen Guo,Xiuli Yang,Pei Shi,Jiamei Yang,Xianzhe Yin,Zhiquan Luo,Jin Xia,Yue Zhou,Mengli Xu,Enjie Liu,Guozhong Jiang,Shenglei Li,Feng Hua Zhao,Chi Ma,Chuanxiang Ma
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:7 (3): 245-253 被引量:90
标识
DOI:10.1016/s2468-1253(21)00378-2
摘要

Camrelizumab, an anti-PD-1 antibody, has shown moderate efficacy in oesophageal squamous cell carcinoma. Apatinib, a selective inhibitor of VEGFR2, has a synergistic effect with immunotherapy. We aimed to assess the combination of camrelizumab and apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma.This single-arm, open-label, phase 2 study was conducted at eight centres in China. Eligible patients were aged 18-75 years, with an Eastern Cooperative Oncology Group performance status of 0 or 1, who had unresectable locally advanced, locally recurrent, or metastatic oesophageal squamous cell carcinoma, and had progressed after or were intolerant to first-line chemotherapy. Patients received intravenous camrelizumab 200 mg once every 2 weeks plus oral apatinib 250 mg once daily for a 28-day cycle until disease progression, unacceptable adverse events, or withdrawal of consent. The primary endpoint was investigator-assessed confirmed objective response rate. Efficacy was analysed in patients who had received at least one dose of study drug, and safety was analysed in patients who received the study drug and had at least one post-baseline safety assessment. The study of this cohort is complete and this trial is registered with ClinicalTrials.gov, number NCT03736863.Between Dec 5, 2019, and Feb 10, 2021, 52 patients were enrolled and included in analyses. At data cutoff (June 20, 2021), median follow-up was 7·5 months (IQR 4·0-11·2). 18 (34·6%, [95% CI 22·0-49·1]) of 52 patients had a confirmed objective response. 23 (44%) of 52 patients had grade 3 or worse treatment-related adverse events. The most common grade 3 or worse treatment-related adverse events were increased aspartate aminotransferase (10 [19%]), increased gamma-glutamyltransferase (10 [19%]), and increased alanine aminotransferase (five [10%]). No treatment-related deaths occurred.Camrelizumab combined with apatinib showed promising activity and manageable toxicity, and might be a potential second-line treatment option for patients with advanced oesophageal squamous cell carcinoma. Another cohort of this study, enrolling patients previously treated with first-line immunotherapy, is ongoing.Jiangsu Hengrui Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
Owen的应助被ppp采纳,获得10
1秒前
1秒前
吉伊完成签到 ,获得积分10
2秒前
秋风的应助被jgpiao采纳,获得10
2秒前
爆米花的应助被落后访波采纳,获得10
2秒前
大个的应助被leee采纳,获得10
2秒前
nnyy发布了新的文献求助10
2秒前
3秒前
隐形曼青的应助被hamster666采纳,获得10
3秒前
完美世界的应助被xiaoo七采纳,获得10
4秒前
YQ的应助被markowits采纳,获得10
5秒前
vvt发布了新的文献求助10
5秒前
胡萝卜完成签到 ,获得积分10
5秒前
斯文败类的应助被科研的麦兜采纳,获得10
5秒前
无敌的ybk完成签到,获得积分20
6秒前
6秒前
7秒前
Akim的应助被haojiewang采纳,获得10
7秒前
7秒前
7秒前
juphen2发布了新的文献求助10
7秒前
lx的应助被拼搏的月亮采纳,获得10
7秒前
h11发布了新的文献求助10
8秒前
Kannan发布了新的文献求助10
8秒前
8秒前
8秒前
zzkkzz发布了新的文献求助10
9秒前
Ray的应助被huanggaga采纳,获得10
10秒前
10秒前
Gary完成签到,获得积分10
10秒前
10秒前
11秒前
11秒前
11秒前
嘻嘻哈哈的应助被YAYA采纳,获得10
11秒前
职克琪发布了新的文献求助10
11秒前
liuww0778完成签到,获得积分10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164555
求助须知:如何正确求助?哪些是违规求助? 9558341
关于积分的说明 21745170
捐赠科研通 7755092
什么是DOI,文献DOI怎么找? 3428591
关于科研通互助平台的介绍 2553128
邀请新用户注册赠送积分活动 2473151